PD-1, PD-L1, and CTLA-4 inhibitors are often used to treat metastatic TNBC, HR-positive (HR+), and HER2-negative (HER2−) breast cancers, respectively [1,46,63]. The gene discussed is ERBB2; the disease is breast carcinoma.